skip to content

Annual Results

SkinBioTherapeutics loss deepens

05 October 2017 07:10

SkinBioTherapeutics posted a deeper annual loss after it continued to invest in the development of potential skin treatments.

The company booked a net loss of £645,554, deepening from a £4,201 loss in the previous year.

At June 30, SkinBioTherapeutics had a cash balance of £3.9m, following its listing on the AIM in April.

"During the year, we have demonstrated three significant properties - barrier improvement, anti-infection and repair - which form the foundations of our three development programmes. We are making good scientific headway and are starting initial discussions with partners," chief executive Cath O'Neill said.

Story provided by

Related Company: SBTX

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.